Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 66.50
Bid: 65.00
Ask: 68.00
Change: 0.00 (0.00%)
Spread: 3.00 (4.615%)
Open: 66.50
High: 66.50
Low: 66.50
Prev. Close: 66.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NetScientific Forms New Digital Health Company

1 May 2015 07:00

RNS Number : 9480L
NetScientific PLC
01 May 2015
 

NetScientific plc

("NetScientific" or the "Group")

 

NetScientific forms digital health company withUS hospital group, Meridian Health

 

Triventis Health LLC will commercialiseadvanced patient management solutions

 

1 May 2015: NetScientific (AIM: NSCI), the biomedical and healthcare technology group, has formed a new digital health sales and marketing subsidiary company, Triventis Health LLC ("Triventis") in partnership with iMPak Health, LLC ("iMPak"), a wholly owned subsidiary of Meridian Health Hospital Group, New Jersey, USA.

 

Triventis will provide smart digital healthcare solutions, enabling better patient data collection, connectivity and software to give healthcare providers actionable clinical data.

 

The new company will have its own sales force to sell and market the integrated solutions provided by a combination of Wanda Health's (a NetScientific subsidiary) cloud-based information analytics and iMPak's healthcare expertise and innovative easy-to-use medical devices, to intelligently monitor and manage patients.

 

This unique healthcare management product has undergone trial and will be adopted by the Meridian Hospital Group - which consists of six hospitals, 100 facility locations and generates US$1.6 billion in revenue. The product will then roll out across the USA to other healthcare providers.

 

The initial product provides continuous monitoring and assessment of patients with Congestive Heart Failure (CHF). Triventis will distribute other Wanda Health applications, notably for patients with co-morbidities and iMPak's next generation medication management to help improve compliance with prescription schedules.

 

Sir Richard Sykes, Chairman of NetScientific, said: "Keeping patients with chronic diseases out of hospital and managed in their homes is of critical importance to all hospital groups and providers worldwide. Our new partnership in the USA with Meridian Health and iMPak, working with Wanda Health analytics, will demonstrate how our combined expertise and technologies can improve patient well-being and reduce costs for providers."

 

Sal Inciardi, Senior Vice President of Business Development, Meridian Heath, said: "Triventis Health is dedicated to significantly enhancing how medical care is delivered. By integrating two key capabilities - healthcare solutions, and health information compilation and analytics - the company's products and services help healthcare practitioners make timely, more effective treatment decisions and improve outcomes for individuals living with a range of chronic diseases. We believe that we are uniquely positioned to enable customers to reduce the cost of healthcare associated with managing chronic disease, addressing what may be the greatest burden faced by most health systems around the world today."

 

-Ends-

 

Notes to Editors

About NetScientific

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.NetScientific.net

About Wanda Health

 

Wanda Health is developing cloud-based analytics, as part of a total patient management solution, in partnership with other healthcare providers. The core analytics engine is based on 12 years of research at the Wireless Health Institute at UCLA. Wanda Health has completed development of a predictive analytics engine for use in remotely monitoring patients with Congestive Heart Failure, the leading cause of hospital re-admissions in USA.

 

About iMPak Health

(A wholly owned subsidiary of Meridian Health)

 

iMPak Health's mission is to develop innovative, easy-to-use devices to screen, diagnose and monitor health conditions through wireless technology. iMPak Health believes in the power of the individual. Their low cost, easy to use mobile health solutions are designed to help individuals assess, track and manage a variety of health conditions including cardiac health, COPD, diabetes, weight, asthma and others. The data collected can easily be shared with their physician for a complete personal health management solution. For more information about iMPak Health, visit www.impakhealth.com.

 

About Meridian Health

Meridian Health is a leading not-for-profit healthcare organization in New Jersey, comprising six hospitals and Meridian Partner Companies that include home health services, skilled nursing and rehabilitation centers, ambulatory care, ambulance services, fitness and wellness centers, and outpatient centers. With more than 100 convenient locations, over 1,800 beds, nearly 13,000 team members, and affiliations with more than 2,000 of the area's finest physicians, Meridian Health is a leading health care provider in New Jersey, providing quality health services, facilities, and programs. In September 2014, Meridian Health and Raritan Bay Medical Center signed a Letter of Intent to merge. In October 2014, Meridian Health and Hackensack University Health Network signed a Memorandum of Understanding to merge. For more information, please visit www.MeridianHealth.com.

 

NetScientific

Peter Thoms, CFO

Tel: +44 (0)77 2055 5752

Investec

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSDMFUSFISEIL
Date   Source Headline
13th Dec 20217:00 amRNSMartlet Capital Update
6th Dec 20212:53 pmRNSPDS Phase 2 Clinical Trial Update
26th Nov 20217:00 amRNS$1million investment in portfolio company, EpiBone
10th Nov 20211:58 pmRNSPDS Reports Q3 2021 Results & Business Update
4th Nov 20217:00 amRNSSofant Signs EUR7.3m ESA Contract
1st Nov 20212:16 pmRNSPDS to License Novel Proteins for Flu Vaccine
26th Oct 20217:00 amRNSEMV Capital Participates in £843k Sofant Funding
22nd Oct 202111:18 amRNSProAxsis announces the approval of a key US patent
22nd Oct 20219:04 amRNSHolding(s) in Company
21st Oct 20214:40 pmRNSSecond Price Monitoring Extn
21st Oct 20214:35 pmRNSPrice Monitoring Extension
21st Oct 20212:17 pmRNSPDS Phase 2 Clinical Trial Update
5th Oct 20217:00 amRNSPDS Phase 2 Clinical Trial Update
4th Oct 20217:00 amRNSInvestor Presentations
30th Sep 202110:22 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSGrant of Options to Directors
29th Sep 20217:00 amRNSInterim Results
20th Sep 20217:00 amRNSNotice of Results and Analyst Briefing
16th Sep 20217:00 amRNSInvestment in Martlet Capital Limited
9th Aug 20215:59 pmRNSHolding(s) in Company
30th Jul 20219:12 amRNSHolding(s) in Company
26th Jul 20214:25 pmRNSHolding(s) in Company
22nd Jul 20214:29 pmRNSHolding(s) in Company
20th Jul 20212:05 pmRNSSecond Price Monitoring Extn
20th Jul 20212:00 pmRNSPrice Monitoring Extension
16th Jul 202110:35 amRNSDirector/PDMR Shareholding
1st Jul 202112:08 pmRNSHolding(s) in Company
30th Jun 20213:42 pmRNSHolding(s) in Company
30th Jun 202110:29 amRNSHolding(s) in Company
30th Jun 202110:27 amRNSHolding(s) in Company
28th Jun 20213:18 pmRNSResult of General Meeting, TVR & PDMR Dealings
22nd Jun 20217:00 amRNSPDS Announces Closing of c. $52m Public Offering
16th Jun 20217:00 amRNSNSCI Participates in $45m PDS Equity Issue
15th Jun 20217:00 amRNSPDS announces proposed offering of common stock
10th Jun 202112:56 pmRNSResult of Placing and Total Voting Rights
10th Jun 20217:00 amRNSProposed Placing
9th Jun 20214:40 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension
8th Jun 20214:36 pmRNSPrice Monitoring Extension
8th Jun 20211:40 pmRNSPDS Announces Release of PDS0101 Interim Data
8th Jun 202111:05 amRNSSecond Price Monitoring Extn
8th Jun 202111:00 amRNSPrice Monitoring Extension
7th Jun 20214:40 pmRNSSecond Price Monitoring Extn
7th Jun 20214:35 pmRNSPrice Monitoring Extension
7th Jun 20212:06 pmRNSSecond Price Monitoring Extn
7th Jun 20212:00 pmRNSPrice Monitoring Extension
7th Jun 20217:00 amRNSProAxsis Update
3rd Jun 20214:30 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.